HUTCHMED (China) vs Protagonist Therapeutics
HCM and PTGX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How HCM and PTGX compare
Protagonist Therapeutics grew revenue faster over the last twelve months (164% versus −13.0% for HUTCHMED (China)).
HUTCHMED (China) keeps more of each dollar of sales as profit, with a net margin of 83.3% compared with 62.0% at Protagonist Therapeutics.
Protagonist Therapeutics scores higher on the StockData Score (16 against 5 for HUTCHMED (China)), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | HCM | PTGX |
|---|---|---|
| Size and price | ||
| Market cap | – | $8.5B |
| Share price | $14.90 | $130.95 |
| Change, 1 year | −2.5% | 54.3% |
| Change, 5 years | −51.5% | 274% |
| Beta (5Y) | 0.97 | 0.78 |
| Employees | 109 | 132 |
| StockData Score | ||
| Total score | 5 | 16 (better) |
| Valuation score | 0 | 4 (better) |
| Growth score | 0 | 2 (better) |
| Performance score | 3 | 4 (better) |
| Health score | 2 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 27.7× |
| P/S | – | 15.4× |
| P/B | – | 7.8× |
| EV/EBITDA | – | 23.6× |
| P/FCF | – | 77.6× |
| FCF yield | – | 1.3% |
| Fair value | – | $183.25 |
| Margin of safety | – | 28.5% |
| Growth | ||
| Revenue growth (TTM) | −13.0% | 164% (better) |
| Revenue growth, 5Y average | 19.2% (better) | 10.0% |
| Net income growth (TTM) | 1111% (better) | 646% |
| EPS growth (TTM) | 1200% (better) | 661% |
| Profitability | ||
| Gross margin | 38.7% | – |
| Operating margin | −7.1% | 58.6% (better) |
| Net margin | 83.3% (better) | 62.0% |
| FCF margin | −14.4% | 19.8% (better) |
| Return on equity | 36.7% | 39.6% (better) |
| Return on invested capital | – | 178% |
| Financial health | ||
| Debt / equity | 0.09 (better) | 0.00 |
| Interest coverage | −13.7× | – |
| Current ratio | 5.64 | 19.85 (better) |
| Altman Z-score | – | 84.88 |
| Piotroski F-score | 4 | 5 (better) |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | 0.51% | 117% |
| Held by insiders | 0.44% | 1.7% |
| Insider net buying, 12 months | – | −$95.0M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | – | 16.1% |
Go deeper
- HCM stock overview
- HCM income statement
- HCM valuation and score
- PTGX stock overview
- PTGX income statement
- PTGX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.